KUALA LUMPUR, April 8 (Bernama) -- Curium, a world leader in nuclear medicine, has entered into an agreement with Eczacıbaşı Holding and Bozlu Group for the acquisition of Eczacıbaşı-Monrol Nuclear Product Co (Monrol), a dedicated specialist in nuclear medicine.
The acquisition is expected to bring together highly complementary geographical footprints, lutetium-177 (Lu-177) capabilities, and positron emission tomography (PET) & single-photon emission computed tomography (SPECT) nuclear medicine infrastructure, as well as facilitate the development of cutting-edge radionuclides and radiopharmaceuticals pipelines for diagnostic and therapeutic purposes.
Curium International Markets Chief Executive Officer, Chaitanya Tatineni in a statement said: “We are extremely pleased to have reached an agreement for the acquisition of Eczacıbaşı-Monrol – building on our existing strong partnership and the commitment of both companies to transform the lives of patients around the world.
“Eczacıbaşı-Monrol’s complementary PET network, Lu-177 capacity, extensive manufacturing and logistics infrastructure, and location as a global distribution hub offers significant benefits for patients requiring life-changing diagnostic and therapeutic solutions once the transaction is completed.”
Meanwhile, Eczacıbaşı-Monrol General Manager, Aydin Kucuk said the company is excited about the benefits of integrating with Curium’s global footprint, product portfolio, and innovations in theranostics for the millions of patients that it serves.
Importantly, the acquisition will add significant Lu-177 manufacturing capacity to Curium to meet the growing demand for Lu-177 worldwide for the benefit of more than 100,000 critically ill patients over the next five years.
It will expand Curium’s PET footprint of 34 sites in Western Europe and Asia with the addition of 12 owned and partnered sites in Eastern Europe and the Middle East and North Africa (MENA) regions.
In addition, Eczacıbaşı-Monrol’s manufacturing and logistics infrastructure in Istanbul, Turkey, will add significant scale to Curium’s vertically integrated production and distribution capabilities.
The completion of this transaction is contingent upon meeting customary closing conditions, including regulatory approvals. Both companies are fully committed to navigating through this process efficiently and expect to finalise the transaction in due course.
The parties expect to be able to close this transaction once the customary regulatory approvals will have been obtained.
-- BERNAMA
No comments:
Post a Comment